NASDAQ: NVNOEnvveno Medical Corp Stock
$5.18-0.05 (-0.96%)
Updated Apr 26, 2024
NVNO Price
$5.18
Fair Value Price
$0.18
Market Cap
$68.98M
52 Week Low
$2.51
52 Week High
$6.97
P/E
-2.71x
P/B
1.49x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$23.52M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.05
Operating Cash Flow
-$19M
Beta
0.9
Next Earnings
May 6, 2024
Ex-Dividend
N/A
Next Dividend
N/A
NVNO Overview
enVVeno Medical Corporation, a medical device company, focuses on the development of various bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous diseases. The company's lead product is the VenoValve, a surgical implant being developed for the treatment of severe deep venous chronic venous insufficiency. Its VenoValve is implanted in the femoral vein and acts as a one-way valve to help restore proper blood flow in the leg. The company was formerly known as Hancock Jaffe Laboratories, Inc. and changed its name to enVVeno Medical Corporation in October 2021. enVVeno Medical Corporation was incorporated in 1999 and is based in Irvine, California.
Zen Score
–
Industry Average (27)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how NVNO scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
NVNO ($5.18) is overvalued by 2,772.82% relative to our estimate of its Fair Value price of $0.18 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
NVNO ($5.18) is not significantly undervalued (2,772.82%) relative to our estimate of its Fair Value price of $0.18 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
NVNO is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more NVNO due diligence checks available for Premium users.
Be the first to know about important NVNO news, forecast changes, insider trades & much more!
NVNO News
Valuation
NVNO fair value
Fair Value of NVNO stock based on Discounted Cash Flow (DCF)
Price
$5.18
Fair Value
$0.18
Overvalued by
2,772.82%
NVNO ($5.18) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
NVNO ($5.18) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
NVNO is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
NVNO price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.71x
Industry
28.63x
Market
41.14x
NVNO price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.49x
Industry
3.7x
NVNO is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
NVNO's financial health
Profit margin
Revenue
$0.0
Net Income
-$5.6M
Profit Margin
0%
NVNO's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$48.6M
Liabilities
$2.4M
Debt to equity
0.05
NVNO's short-term assets ($46.92M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
NVNO's short-term assets ($46.92M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
NVNO's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
NVNO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$5.0M
Investing
-$22.1M
Financing
$0.0
NVNO's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
NVNO vs Medical Device Stocks
Envveno Medical Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.